A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Mati Therapeutics Inc.83 enrolled

Overview

The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Glaucoma Ocular Hypertension

Interventions

Formulation E1 of L-PPDSDRUG

Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

Formulation E2 of L-PPDSDRUG

Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects over 18 years of age diagnosed with ocular hypertension or open-angle glaucoma * Subjects who have a best corrected visual acuity of 20/100 or better Exclusion Criteria: * Subjects who wear contact lenses * Subjects who have uncontrolled medical conditions * Subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic ocular topical medications * Subjects who have a history of chronic or recurrent inflammatory eye disease

Locations (1)

Unnamed facility

Menlo Park, California, United States

Outcomes

Primary Outcomes

IOP change from baseline

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.